Fig. 4: The impact of HSPG2 expression on survival in AML patients.
From: HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia
a overall survival (OS) among whole-cohort AML. b OS among non-M3 AML. c OS among CN-AML. d leukemia-free survival (LFS) among whole-cohort AML. e LFS among non-M3 AML. f LFS among CN-AML. Non-M3 AML non M3 acute myeloid leukemia, CN-AML cytogenetically normal acute myeloid leukemia.
